Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer

R. Charles Coombes, Judith M. Bliss, Marc Espie, Frans L. G. Erdkamp, Jacob Wals, Alejandro Tres, Michel Marty, Robert E. Coleman, Nicole Tubiana-Mathieu, Marinus O. den Boer, Andrew Wardley, Lucy S. Kilburn, Derek Cooper, Marina W. K. Thomas, Justine A. Reise, Katie Wilkinson, Pierre Hupperets

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3247-3254
JournalJournal of Clinical Oncology
Volume29
Issue number24
DOIs
Publication statusPublished - 20 Aug 2011

Cite this

Coombes, R. C., Bliss, J. M., Espie, M., Erdkamp, F. L. G., Wals, J., Tres, A., Marty, M., Coleman, R. E., Tubiana-Mathieu, N., den Boer, M. O., Wardley, A., Kilburn, L. S., Cooper, D., Thomas, M. W. K., Reise, J. A., Wilkinson, K., & Hupperets, P. (2011). Randomized, Phase III Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin Alone in Postmenopausal Patients With Node-Positive Breast Cancer. Journal of Clinical Oncology, 29(24), 3247-3254. https://doi.org/10.1200/JCO.2010.32.7254